Literature DB >> 19210739

Using regression models to analyze randomized trials: asymptotically valid hypothesis tests despite incorrectly specified models.

Michael Rosenblum1, Mark J van der Laan.   

Abstract

Regression models are often used to test for cause-effect relationships from data collected in randomized trials or experiments. This practice has deservedly come under heavy scrutiny, because commonly used models such as linear and logistic regression will often not capture the actual relationships between variables, and incorrectly specified models potentially lead to incorrect conclusions. In this article, we focus on hypothesis tests of whether the treatment given in a randomized trial has any effect on the mean of the primary outcome, within strata of baseline variables such as age, sex, and health status. Our primary concern is ensuring that such hypothesis tests have correct type I error for large samples. Our main result is that for a surprisingly large class of commonly used regression models, standard regression-based hypothesis tests (but using robust variance estimators) are guaranteed to have correct type I error for large samples, even when the models are incorrectly specified. To the best of our knowledge, this robustness of such model-based hypothesis tests to incorrectly specified models was previously unknown for Poisson regression models and for other commonly used models we consider. Our results have practical implications for understanding the reliability of commonly used, model-based tests for analyzing randomized trials.

Entities:  

Mesh:

Year:  2009        PMID: 19210739      PMCID: PMC2748134          DOI: 10.1111/j.1541-0420.2008.01177.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements.

Authors:  Adrián V Hernández; Ewout W Steyerberg; J Dik F Habbema
Journal:  J Clin Epidemiol       Date:  2004-05       Impact factor: 6.437

3.  A randomized trial of inhaled cyclosporine in lung-transplant recipients.

Authors:  Aldo T Iacono; Bruce A Johnson; Wayne F Grgurich; J Georges Youssef; Timothy E Corcoran; Deidre A Seiler; James H Dauber; Gerald C Smaldone; Adriana Zeevi; Samuel A Yousem; John J Fung; Gilbert J Burckart; Kenneth R McCurry; Bartley P Griffith
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

4.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

5.  Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.

Authors:  Nancy S Padian; Ariane van der Straten; Gita Ramjee; Tsungai Chipato; Guy de Bruyn; Kelly Blanchard; Stephen Shiboski; Elizabeth T Montgomery; Heidi Fancher; Helen Cheng; Michael Rosenblum; Mark van der Laan; Nicholas Jewell; James McIntyre
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

6.  Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

  6 in total
  16 in total

1.  Simple, efficient estimators of treatment effects in randomized trials using generalized linear models to leverage baseline variables.

Authors:  Michael Rosenblum; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010-04-01       Impact factor: 0.968

2.  On the robustness of tests of genetic associations incorporating gene-environment interaction when the environmental exposure is misspecified.

Authors:  Eric J Tchetgen Tchetgen; Peter Kraft
Journal:  Epidemiology       Date:  2011-03       Impact factor: 4.822

3.  On adjustment for auxiliary covariates in additive hazard models for the analysis of randomized experiments.

Authors:  S Vansteelandt; T Martinussen; E Tchetgen Tchetgen
Journal:  Biometrika       Date:  2013-11-21       Impact factor: 2.445

4.  Improving massive experiments with threshold blocking.

Authors:  Michael J Higgins; Fredrik Sävje; Jasjeet S Sekhon
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

5.  Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes.

Authors:  Phillip J Schulte; Anastasios A Tsiatis; Eric B Laber; Marie Davidian
Journal:  Stat Sci       Date:  2014-11       Impact factor: 2.901

6.  Testing for gene-environment interaction under exposure misspecification.

Authors:  Ryan Sun; Raymond J Carroll; David C Christiani; Xihong Lin
Journal:  Biometrics       Date:  2017-11-09       Impact factor: 2.571

7.  A broad symmetry criterion for nonparametric validity of parametrically based tests in randomized trials.

Authors:  Russell T Shinohara; Constantine E Frangakis; Constantine G Lyketsos
Journal:  Biometrics       Date:  2011-07-15       Impact factor: 2.571

8.  Were the mental health benefits of a housing mobility intervention larger for adolescents in higher socioeconomic status families?

Authors:  Quynh C Nguyen; Nicole M Schmidt; M Maria Glymour; David H Rehkopf; Theresa L Osypuk
Journal:  Health Place       Date:  2013-05-24       Impact factor: 4.078

9.  Gender and crime victimization modify neighborhood effects on adolescent mental health.

Authors:  Theresa L Osypuk; Nicole M Schmidt; Lisa M Bates; Eric J Tchetgen-Tchetgen; Felton J Earls; M Maria Glymour
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

10.  Identifying predictive markers for personalized treatment selection.

Authors:  Yuanyuan Shen; Tianxi Cai
Journal:  Biometrics       Date:  2016-03-21       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.